UPDATE: Raymond James Maintains Strong Buy On Gilead, Lowers Target To $81 Notes 'our investment thesis is admittedly drifting'; Doesn't 'think Biktarvy + PrEP + Yescarta are enough anymore to drive growth in the face of continued pressure on HCV'